(VIANEWS) – Shares of ABIVAX (CAC 40: ABVX.PA) dropped by a staggering 10.98% to €13.14 at 11:37 EST on Thursday, after two consecutive sessions in a row of losses. CAC 40 is jumping 0.4% to €7,496.44, after three sequential sessions in a row of losses. This seems, up to now, a somewhat bullish trend trading session today.
ABIVAX’s last close was €14.76, 42.12% below its 52-week high of €25.50.
About ABIVAX
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ABIVAX has a trailing twelve months EPS of €-2.71.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1286.47%.
Yearly Top and Bottom Value
ABIVAX’s stock is valued at €13.14 at 11:37 EST, way below its 52-week high of €25.50 and way above its 52-week low of €5.60.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ABIVAX’s stock is considered to be overbought (>=80).
More news about ABIVAX (ABVX.PA).
